Purpose: Response to standard oncologic treatment is limited in colorectal cancer. The gene
expression–based consensus molecular subtypes (CMS) provide a new paradigm for …

Colorectal cancers (CRCs) can be divided into four gene expression-based biologically
distinct consensus molecular subtypes (CMS). This classification provides a potential …

Personalized cancer medicine is becoming increasingly important in colorectal cancer
treatment. Especially for targeted therapies, large variations between individual treatment …

Background Colorectal cancer (CRC) is a heterogeneous and biologically poorly
understood disease. To tailor CRC treatment, it is essential to first model this heterogeneity …

Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide.
Similar to many other malignancies, CRC is a heterogeneous disease, making it a clinical …

Colorectal cancer (CRC) is a highly heterogeneous disease both from a molecular and
clinical perspective. Several distinct molecular entities, such as microsatellite instability …

Colorectal cancers (CRCs) are the third leading cause of cancer-related mortality worldwide.
Rather than being a single, uniform disease type, accumulating evidence suggests that …

Molecular subtypes-based therapies offer new potential framework for desired and precise
outcome in clinical settings. Current treatment strategies in colorectal cancer are largely 'one …

The classification of colorectal cancer (CRC) plays a pivotal role in predicting a patient's
prognosis and determining treatment strategies. The consensus molecular subtype (CMS) …

Colorectal cancer (CRC) is characterized by major inter-tumor diversity that complicates the
prediction of disease and treatment outcomes. Recent efforts help resolve this by sub …